J. W. Mouton, H. P. Endtz, J. G. den Hollander, N. van den Braak and H. A. Verbrugh

Size: px
Start display at page:

Download "J. W. Mouton, H. P. Endtz, J. G. den Hollander, N. van den Braak and H. A. Verbrugh"

Transcription

1 Journal of Antimicrobial Chemotherapy (1997) 39, Suppl. A, JAC In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis J. W. Mouton, H. P. Endtz, J. G. den Hollander, N. van den Braak and H. A. Verbrugh Department of Clinical Microbiology, Erasmus University Hospital Rotterdam, Dr Molewaterplein 40, 3015 gd Rotterdam, The Netherlands The activity of quinupristin/dalfopristin was compared with that of other widely used antibiotics against 355 strains isolated from patients with endocarditis. MICs were determined by a standard agar dilution method. Quinupristin/dalfopristin was inhibitory at 1 mg/l for all coagulase-negative staphylococci (n = 36) and for the majority of Staphylococcus aureus strains (n = 87). The activity of quinupristin/dalfopristin against 186 viridans streptococci was somewhat dependent on the species, with MIC 50 s ranging from 0.5 to 2 mg/l, being least active against Streptococcus bovis and most active against Streptococcus gordonii and Streptococcus mitis. For the staphylococci, quinupristin/dalfopristin was as active against erythromycin-susceptible as erythromycin-resistant strains. Viridans streptococci showed a slight but significant correlation between sensitivity to erythromycin and quinupristin/dalfopristin. It is concluded that quinupristin/dalfopristin has the potential to treat serious infections such as endocarditis caused by Gram-positive cocci. Introduction Quinupristin/dalfopristin, a recently developed streptogramin antibiotic, is the first of its class available clinically for intravenous use. Most Gram-positive bacteria are susceptible to quinupristin/dalfopristin, 1 3 and its chief use would be in patients with suspected or proven infections caused by Gram-positive microorganisms, such as soft tissue infections due to streptococci and staphylococci. Since the mechanism of action, and therefore the development of resistance, is distinct from that of presently used antibiotics, 4,5 it may be particularly useful for treating patients with serious infections due to multi-resistant microorganisms. 6 Another possible indication would be endocarditis due to Gram-positive cocci. These infections are still difficult to treat in many cases, and because of increasing resistance the responsible microorganisms, will be even more difficult to treat in the future. To determine the potential of quinupristin/dalfopristin as treatment for these infections, its activity was compared with that of other frequently used antibiotics against Gram-positive cocci isolated from patients with endocarditis. Materials and methods Strains Strains were isolated from patients with endocarditis in The Netherlands during the period 1 November 1986 to 1 November These strains have been described extensively. 7 In brief, 419 strains were collected and identified, 326 from native valve endocarditis and 93 from prosthetic valve endocarditis. Of these, 64 were not Gram-positive cocci, or could not be recovered. The remaining 355 strains were used. Strains were identified by standard procedures, 8 as described by van der Meer et al. 7 All viridans streptococci were re-identified using the RAPID ID32 Strep system (biomérieux, Marcyl Etoile, France). Antibiotics Antibiotics were supplied as reference powders by their respective manufacturers in The Netherlands: quinupristin/dalfopristin (Rhône-Poulenc Rorer, Amstel- Tel: ; Fax: The British Society for Antimicrobial Chemotherapy 75

2 J. W. Mouton et al. veen), vancomycin (Eli Lilly, Nieuwegein), rifampicin, penicillin and teicoplanin (Yamanouchi Pharma, Leiderdorp), clindamycin (Upjohn, Amstelveen), clarithromycin and erythromycin (Abbott, Amstelveen), amoxycillin and flucloxacillin (Smith-Kline Beecham, Rijswrijk), cefuroxime (Glaxo, Zeist), cefotaxime (Hoechst-Marion- Roussel, Hoevelaken), gentamicin (Schering-Plough, Amstelveen), minocycline (Wyeth-Lederle, Hoofddorp). Stock solutions were prepared according to the recommendations of the National Committee for Clinical Laboratory Standards. 9 MIC determination MICs were determined by a standard agar dilution method. 10 Freshly prepared, serial two-fold dilutions of each antibiotic were incorporated in Mueller Hinton (Difco, Amsterdam, The Netherlands). Overnight Mueller Hinton broth cultures of the isolates were adjusted to a turbidity equivalent to a 0.5 McFarland standard and an inoculum of 10 4 cfu was delivered to the surface of the agar plates with a multipoint inoculator. The MIC was defined as the lowest concentration of each antibiotic which inhibited visible growth after incubation for 18 h at 37 C. Three control strains, Staphylococcus aureus ATCC 29213, Streptococcus pneumoniae ATCC and Enterococcus faecalis ATCC 29212, were included as a control in each batch. Results were analysed using the SAS computer program package. 11 Results The MIC 50 and MIC 90 and MIC range of quinupristin/ dalfopristin and comparative agents for the bacteria tested are shown in Tables I and II. For staphylococci, quinupristin/dalfopristin was inhibitory at 1 mg/l for all coagulase-negative staphylococci and for the majority of S. aureus strains. Quinupristin/dalfopristin was more active than vancomycin and teicoplanin for the coagulasenegative staphylococci. For -haemolytic streptococci, the activity of quinupristin/dalfopristin was similar to that of vancomycin and slightly less than that of teicoplanin. The two macrolides studied, clarithromycin and erythromycin, were both more active than quinupristin/dalfopristin against these strains. The activity of quinupristin/dalfopristin was not very high for the E. faecalis, the MIC 50 being 8 mg/l; vancomycin and teicoplanin were more active against these isolates. The activity of quinupristin/ dalfopristin against the 186 strains of Streptococcus bovis and viridans streptococci was slightly dependent on the species (Table II) with MIC 50 s ranging from 0.5 to 2 mg/l. Quinupristin/dalfopristin was least active against S. bovis and most active against Streptococcus gordonii and Streptococcus mitis. However, for all species, the range of activity within each species was quite large, indicating much interstrain variability. Except for S. bovis, activity was similar to that of vancomycin, while being less than that of teicoplanin. Quinupristin/dalfopristin was less active than erythromycin and clarithromycin. Since there is a common target for streptogramins and macrolides, 12 potential cross-resistance between erythromycin and quinupristin/dalfopristin was examined amongst staphylococci and the viridans streptococci (Table III). For the staphylococci, there appeared to be no cross-resistance. The majority of both erythromycinsusceptible and erythromycin-resistant isolates were inhibited by quinupristin/dalfopristin at concentrations of 1 mg/l. In contrast, erythromycin-resistant strains of viridans streptococci were slightly less sensitive than erythromycin-sensitive strains. Correlation analysis between susceptibility of erythromycin and quinupristin/ dalfopristin showed statistical significance (r 0.174; P 0.02). Discussion This study showed that quinupristin/dalfopristin is active against staphylococci and streptococci isolated from patients with endocarditis, the only exception being E. faecalis, which appeared only moderately susceptible. The majority of the strains were susceptible to concentrations achieved in vivo, 13 and quinupristin/dalfopristin could therefore be a suitable agent for treating infections due to staphylococci and streptococci. The somewhat lower activity against E. faecalis has been found by other workers. 14 The range of activity was large, however, and there might be occasions when the drug could be used. The alternative agents, vancomycin and teicoplanin, have similar activity, with teicoplanin being slightly more active. One of the disadvantages of the glycopeptides for treating endocarditis, however, is that these molecules are large, and their penetration into vegetations is not optimal. 15 However, in a rabbit model of aortic valve endocarditis, vancomycin was slightly more active than quinupristin/ dalfopristin. 16 For clinical use quinupristin/ dalfopristin may be an alternative in patients with endocarditis due to Gram-positive cocci that cannot be treated with standard therapy with -lactam antibiotics. Although we tested no methicillin-resistant isolates in this study, other studies have shown similar activity of quinupristin/ dalfopristin against methicillin- and susceptible-resistant staphylococci. 2,17,18 The streptogramins, lincosamides and macrolides have a common target, namely the 23S ribosomal RNA. 12 Different mechanisms of resistance have been described To determine whether there was cross-resistance between quinupristin/dalfopristin and the macrolides, we looked at the susceptibility of quinupristin/dalfopristin in erythromycin-susceptible and erythromycin-resistant strains. For staphylococci, we found no difference between these 76

3 Quinupristin/dalfopristin against endocarditis isolates Table I. Comparative in-vitro activity of quinupristin/dalfopristin and other antibiotics against Gram-positive cocci isolated from patients with endocarditis Species (number of strains) MIC 50 MIC 90 MIC range and antibiotic (mg/l) (mg/l) (mg/l) S. aureus (87) penicillin quinupristin/dalfopristin rifampicin vancomycin teicoplanin flucloxacillin cefuroxime clindamycin clarithromycin erythromycin Coagulase-negative staphylococci (36) penicillin quinupristin/dalfopristin rifampicin vancomycin teicoplanin flucloxacillin cefuroxime clindamycin clarithromycin erythromycin E. faecalis (35) amoxycillin quinupristin/dalfopristin minocycline vancomycin teicoplanin clindamycin clarithromycin erythromycin gentamicin Haemolytic streptococci (11) penicillin amoxycillin quinupristin/dalfopristin vancomycin teicoplanin cefuroxime cefotaxime clindamycin clarithromycin erythromycin

4 J. W. Mouton et al. Table II. Comparative in-vitro activity of quinupristin/dalfopristin and other antibiotics against viridans streptococci isolated from patients with endocarditis Species (number of strains) MIC 50 MIC 90 MIC range and antibiotic (mg/l) (mg/l) (mg/l) S. bovis (19) penicillin amoxycillin quinupristin/dalfopristin vancomycin teicoplanin cefuroxime cefotaxime clindamycin clarithromycin erythromycin gentamicin S. gordonii (23) penicillin amoxycillin quinupristin/dalfopristin vancomycin teicoplanin cefuroxime cefotaxime clindamycin clarithromycin erythromycin gentamicin S. mitis (28) penicillin amoxycillin quinupristin/dalfopristin vancomycin teicoplanin cefuroxime cefotaxime clindamycin clarithromycin erythromycin gentamicin Streptococcus mutans (18) penicillin amoxycillin quinupristin/dalfopristin vancomycin teicoplanin cefuroxime cefotaxime clindamycin clarithromycin erythromycin gentamicin

5 Quinupristin/dalfopristin against endocarditis isolates Table II. Continued Species (number of strains) MIC 50 MIC 90 MIC range and antibiotic (mg/l) (mg/l) (mg/l) Streptococcus oralis (32) penicillin amoxycillin quinupristin/dalfopristin vancomycin teicoplanin cefuroxime cefotaxime clindamycin clarithromycin erythromycin gentamicin Viridans streptococci, other (66) penicillin amoxycillin quinupristin/dalfopristin vancomycin teicoplanin cefuroxime cefotaxime clindamycin clarithromycin erythromycin gentamicin Table III. Cross-resistance to erythromycin and quinupristin/dalfopristin in staphylococci and viridans streptococci Quinupristin/dalfopristin (mg/l) Isolates (number) MIC 50 MIC 90 range S. aureus erythromycin-susceptible (n 83) erythromycin-resistant (n 3) Coagulase-negative staphylococci erythromycin-susceptible (n 8) erythromycin-resistant (n 28) Viridans streptococci erythromycin-susceptible (n 173) erythromycin-resistant (n 13) two groups, indicating the MLS B type of resistance. Hence quinupristin/dalfopristin may be used in treating infections due to erythromycin-resistant strains, 2 despite known cross-resistance between erythromycin and quinupristin. For the viridans streptococci, there was a difference between erythromycin-resistant and erythromycin-susceptible strains with respect to susceptibility to quinupristin/dalfopristin, shown both by the difference in susceptibility between the two groups and a correlation between susceptibility to erythromycin and to quinupristin/dalfopristin. The same was true for clarithromycin (results not shown). This suggests that there is some form of cross-resistance between these agents, probably dependent on the mechanism of resistance of 79

6 J. W. Mouton et al. the individual strain (as indicated by the low correlation (r 0.174), significant only because of the large number of strains tested). It may be concluded that quinupristin/dalfopristin is a potential therapeutic agent for serious infections, such as endocarditis, due to Gram-positive cocci. Although crossresistance to macrolides in viridans streptococci is low, susceptibility of individual strains should be taken into account when considering its use in the treatment of infections. Further clinical studies should be undertaken to determine its role in the treatment of patients with endocarditis due to Gram-positive cocci. References 1. Fass, R. (1991). In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci and enterococci. Antimicrobial Agents and Chemotherapy 35, Brumfitt, W., Hamilton-Miller, J. M. T. & Shah, S. (1992). In-vitro activity of RP 59500, a new semi-synthetic streptogramin antibiotic, against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 30, Suppl. A, Verbist, L. & Verhaegen, J. (1992). Comparative in-vitro activity of RP Journal of Antimicrobial Chemotherapy 30, Suppl. A, Vasquez, D. (1967). Mechanism of action. In The Strepto - gramin Family of Antibiotics, Vol. 1 (Gottlieb, D. & Shaw, D., Eds), pp Springer Verlag, NY. 5. Aumercier, M., Bouhallab, S., Capmau, M.-L. & Le Goffic, F. (1992). RP 59500: a new proposed mechanism for its bacterial activity. Journal of Antimicrobial Chemotherapy 30, Suppl. A, Pechere, J. C. (1992). In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci. Jour - nal of Antimicrobial Chemotherapy 30 Suppl. A, van der Meer, J. T. M., van Vianen, W., Hu, E., van Leeuwen, W., Valkenburg, H. A., Thompson, J. & Michel, M. F. (1991). Distribution, antibiotic susceptibility and tolerance of bacterial isolates in culture-positive cases of endocarditis in the Netherlands. Euro - pean Journal of Clinical Microbiology and Infectious Diseases 10, Facklam, R. R. & Carey, R. B. (1985). Streptococci and aerococci. In Manual of Clinical Microbiology (Lennette, E. H., Balows, A., Hausler, W. J. & Shadomy, H. J., Eds), pp American Society for Microbiology, Washington, DC. 9. National Committee for Clinical Laboratory Standards. (1990). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 2nd edn; Approved Standard M7-A2. NCCLS, Villanova, PA. 10. Sahm, D. F. & Washington, J. A. (1991). Antibacterial susceptibility tests: dilution methods. In Manual of Clinical Micro - biology (Balows, A., Hausler, W. J., Hermann, K. L., Isenberg, H. D. & Shadomy, H. J., Eds.), pp American Society for Microbiology, Washington, DC. 11. SAS Institute Inc. (1990). SAS User s Guide. SAS Institute, Inc., Cary, NC. 12. Weisblum, B. (1985). Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity and structural elements that regulate expression a review. Journal of Antimicrobial Chemotherapy 16, Suppl. A, Etienne, S. D., Maontay, G., Le Liboux, A., Frydman, A. & Garaud, J. J. (1992). A phase I, double-blind, placebo controlled study of the tolerance and pharmacokinetic behaviour of RP Journal of Antimicrobial Chemotherapy 30, Suppl. A, Neu, H. C., Chin, N. & Gu, J. (1992). The in vitro activity of new streptogramins, RP 59500, RP 57669, and RP 54476, alone and in combinations. Journal of Antimicrobial Chemotherapy 30, Suppl. A, Cremieux, A. C., Maziere, B., Vallois, J. M., Ottaviani, M., Azancot, A., Raffoul, H. et al. (1989). Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. Journal of Infectious Diseases 159, Chambers, H. F. (1992). Studies of RP in vitro and in a rabbit model of aortic valve endocarditis caused by methicillinresistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 30, Suppl. A, Soussy, C. J., Acar, J. F., Cluzel, R., Courvalin, P., Duval, J., Fleurette, J. et al. (1992). A collaborative study of the in-vitro sensitivity to RP of bacteria isolated in seven hospitals in France. Journal of Antimicrobial Chemotherapy 3 0, Suppl. A, Hoban, D. J., Weshnoweski, B., Palatnick, L., Zhanel, L. & Davidson, R. L. (1992). In-vitro activity of streptogramin RP against staphylococci, including bacterial kinetic studies. Journal of Antimicrobial Chemotherapy 30, Suppl. A, Duval, J. (1985). Evolution and epidemiology of MLS resistance. Journal of Antimicrobial Chemotherapy 16, Suppl. A, Le Goffic, F., Capmeau, M.-L., Bonnet, D., Cerceau, C., Soussy, C., Dublanchet, A. et al. (1977). Plasmid-mediated pristinamycin resistance. PAC IIA a new enzyme which modifies pristinamycin IIA. Journal of Antibiotics 30, Leclerc, R. & Courvalin, P. (1991). Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrobial Agents and Chemotherapy 35,

Jan A. Jacobs* and Ellen E. Stobberingh

Jan A. Jacobs* and Ellen E. Stobberingh Journal of Antimicrobial Chemotherapy (996) 37, 37-375 In-vitro antimicrobial susceptibility of the 'Streptococcus millerv group {Streptococcus anginosus, Streptococcus constellatus and Streptococcus intermedius)

More information

Tel: Fax:

Tel: Fax: CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.

More information

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062

More information

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ

MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,

More information

against Clinical Isolates of Gram-Positive Bacteria

against Clinical Isolates of Gram-Positive Bacteria ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)

2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time) Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according

More information

EUCAST recommended strains for internal quality control

EUCAST recommended strains for internal quality control EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01

More information

Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci

Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious

More information

Quinupristin-dalfopristin Resistance in Gram-positive Bacteria: Experience from a Tertiary Care Referral Center in North India

Quinupristin-dalfopristin Resistance in Gram-positive Bacteria: Experience from a Tertiary Care Referral Center in North India Original Article 117 Quinupristin-dalfopristin Resistance in Gram-positive Bacteria: Experience from a Tertiary Care Referral Center in North India Antariksh Deep, M.D.*, Nidhi Goel, M.D.*, Rama Sikka,

More information

January 2014 Vol. 34 No. 1

January 2014 Vol. 34 No. 1 January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton

More information

Christiane Gaudreau* and Huguette Gilbert

Christiane Gaudreau* and Huguette Gilbert Journal of Antimicrobial Chemotherapy (1997) 39, 707 712 JAC Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter

More information

Brief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae

Brief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot

More information

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.

More information

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Routine internal quality control as recommended by EUCAST Version 3.1, valid from Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus

More information

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical

More information

Dalbavancin, enterococci, Gram-positive cocci, Latin America, staphylococci, streptococci

Dalbavancin, enterococci, Gram-positive cocci, Latin America, staphylococci, streptococci ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01051.x Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres A. C. Gales 1, H. S. Sader 1,2

More information

Received 17 December 2003; accepted 22 December 2003

Received 17 December 2003; accepted 22 December 2003 Journal of Antimicrobial Chemotherapy (2004) 53, 609 615 DOI: 10.1093/jac/dkh130 Advance Access publication 3 March 2004 In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines,

More information

There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility

There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility ANTIMICROBIAL SUSCEPTIBILITY TESTING ON MILK SAMPLES Method and guidelines There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility

More information

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The

More information

A Norazah, M D*, V K E Lim, FRCPath**, MY Rohani, MPath*, A G M Kamel, MD**,

A Norazah, M D*, V K E Lim, FRCPath**, MY Rohani, MPath*, A G M Kamel, MD**, I ORIGINAL ARTICLE In-Vitro Activity of Quinupristin/ Dalfopristin, Levofloxacin and Moxifloxacin Against Fusidic Acid and Rifampicin-Resistant Strains of Methicillin Resistant Staphylococcus Aureus (MRSA)

More information

Original Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e.

Original Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e. Iranian Journal of Pharmaceutical Research (22), (2): 559-563 Received: January 2 Accepted: June 2 Copyright 22 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services

More information

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What

More information

Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance

Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,

More information

Antimicrobial Activity of Linezolid Against Gram-Positive Cocci Isolated in Brazil

Antimicrobial Activity of Linezolid Against Gram-Positive Cocci Isolated in Brazil BJID 2001; 5 (August) 171 Antimicrobial Activity of Linezolid Against Gram-Positive Cocci Isolated in Brazil Helio S. Sader, Ana C. Gales and Ronald N. Jones Special Clinical Microbiology Laboratory, Division

More information

Saxena Sonal*, Singh Trishla* and Dutta Renu* (Received for publication January 2012)

Saxena Sonal*, Singh Trishla* and Dutta Renu* (Received for publication January 2012) J. Commun. Dis. 44(2) 2012 : 97-102 Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus at a tertiary care hospital: Implications for clinical therapy

More information

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram

More information

Aminoglycoside-resistant enterococci

Aminoglycoside-resistant enterococci Aminoglycoside-resistant enterococci M. J. BASKER, B. SLOCOMBE, AND R. SUTHERLAND From Beecham Pharmaceuticals Research Division, Brockham Park, Betchworth, Surrey J. clin. Path., 1977, 30, 375-380 SUMMARY

More information

56 Clinical and Laboratory Standards Institute. All rights reserved.

56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:

More information

Detection of inducible clindamycin resistance among clinical isolates of Staphylococcus aureus in a tertiary care hospital

Detection of inducible clindamycin resistance among clinical isolates of Staphylococcus aureus in a tertiary care hospital ISSN: 2319-7706 Volume 3 Number 9 (2014) pp. 689-694 http://www.ijcmas.com Original Research Article Detection of inducible clindamycin resistance among clinical isolates of Staphylococcus aureus in a

More information

An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus

An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding

More information

Int.J.Curr.Microbiol.App.Sci (2018) 7(8):

Int.J.Curr.Microbiol.App.Sci (2018) 7(8): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.378

More information

In Vitro Evaluation of a Novel Ketolide Antimicrobial Agent, RU-64004

In Vitro Evaluation of a Novel Ketolide Antimicrobial Agent, RU-64004 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1997, p. 454 459 Vol. 41, No. 2 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology In Vitro Evaluation of a Novel Ketolide Antimicrobial

More information

What s new in EUCAST methods?

What s new in EUCAST methods? What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests

More information

RCH antibiotic susceptibility data

RCH antibiotic susceptibility data RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

Determination of antibiotic sensitivities by the

Determination of antibiotic sensitivities by the Journal of Clinical Pathology, 1978, 31, 531-535 Determination of antibiotic sensitivities by the Sensititre system IAN PHILLIPS, CHRISTINE WARREN, AND PAMELA M. WATERWORTH From the Department of Microbiology,

More information

Detection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital

Detection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 4008-4014 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.415

More information

Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.

Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.

More information

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017 Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,

More information

Ciprofloxacin, Enoxacin, and Ofloxacin against Aerobic and

Ciprofloxacin, Enoxacin, and Ofloxacin against Aerobic and ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1988, p. 1143-1148 Vol., No. 8 0066-4804/88/081143-06$00/0 Copyright 1988, American Society for Microbiology Comparative Activities of, Amoxicillin-Clavulanic

More information

BJID 2001; 5 (February) 21

BJID 2001; 5 (February) 21 BJID 2001; 5 (February) 21 Antimicrobial Susceptibility of Quinupristin/Dalfopristin Tested Against Gram-Positive Cocci From Latin America: Results from the Global SMART (GSMART) Surveillance Study Helio

More information

Brief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents

Brief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents Journal of Antimicrobial Chemotherapy (5) 35, -5 Brief reports Heat stability of the antimicrobial activity of sixty-two antibacterial agents Walter H. Traub and Birgit Leonhard Institut fur Medizinische

More information

British Society for Antimicrobial Chemotherapy

British Society for Antimicrobial Chemotherapy British Society for Antimicrobial Chemotherapy BSAC to actively support the EUCAST Disc Diffusion Method for Antimicrobial Susceptibility Testing in preference to the current BSAC Disc Diffusion Method

More information

This document is protected by international copyright laws.

This document is protected by international copyright laws. Table 2C Table 2C. and s for Product Name: Infobase 2010 - Release Date: February 2010 60 Clinical and Laboratory Standards Institute. All rights reserved. Testing Conditions Medium: diffusion: MHA Broth

More information

MRSA surveillance 2014: Poultry

MRSA surveillance 2014: Poultry Vicky Jasson MRSA surveillance 2014: Poultry 1. Introduction In the framework of the FASFC surveillance, a surveillance of MRSA in poultry has been executed in order to determine the prevalence and diversity

More information

British Society for Antimicrobial Chemotherapy

British Society for Antimicrobial Chemotherapy British Society for Antimicrobial Chemotherapy Standing Committee on Susceptibility Testing Version 13.0, 10-06-2014 Content Page Additional information Changes in version 13 2 Suggestions for appropriate

More information

Annual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)

Annual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml) Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative Journal of Antimicrobial Chemotherapy (2008) 62, 116 121 doi:10.1093/jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates:

More information

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016 Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that

More information

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain

More information

ORIGINAL ARTICLE /j x

ORIGINAL ARTICLE /j x ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01550.x Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002 2004)

More information

Received 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004

Received 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.

More information

Original Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D.

Original Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D. Original Article Vol. 25 No. 2 In vitro activity of daptomycin against MRSA:Trakulsomboon S & Thamlikitkul V. 57 In Vitro Activity of Daptomycin against Methicillin- Resistant Staphylococcus aureus (MRSA)

More information

Comparative Antimicrobial Activities of Linezolid and Vancomycin against Gram-Positive Clinical Isolates from Hospitals in Kuwait

Comparative Antimicrobial Activities of Linezolid and Vancomycin against Gram-Positive Clinical Isolates from Hospitals in Kuwait Original Paper Med Principles Pract 2001;10:177 181 Received: June 24, 2001 Revised: September 29, 2001 Comparative Antimicrobial Activities of Linezolid and Vancomycin against Gram-Positive Clinical Isolates

More information

Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System

Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System Polish Journal of Microbiology 2005, Vol. 54, No 4, 311 316 Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System EL BIETA STEFANIUK*, AGNIESZKA MRÓWKA

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS

More information

EDUCATIONAL COMMENTARY CURRENT METHODS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING

EDUCATIONAL COMMENTARY CURRENT METHODS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Commentary provided by: Linsey Donner, MPH, CPH, MLS (ASCP) CM Assistant Professor, Microbiology and Serology College of Allied Health Professions, Division of Medical Laboratory Science University of

More information

Evaluation of MicroScan MIC Panels for Detection of

Evaluation of MicroScan MIC Panels for Detection of JOURNAL OF CLINICAL MICROBIOLOGY, May 1988, p. 816-820 Vol. 26, No. 5 0095-1137/88/050816-05$02.00/0 Copyright 1988, American Society for Microbiology Evaluation of MicroScan MIC Panels for Detection of

More information

Management of Native Valve

Management of Native Valve Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis

More information

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance

More information

ICAAC. Key words: antibacterial agent development approval. linezolid β. chloramphenicol tetracycline colistin mupirocin teicoplanin

ICAAC. Key words: antibacterial agent development approval. linezolid β. chloramphenicol tetracycline colistin mupirocin teicoplanin 16 11 1 16 11 25 58 238 154 β 65 25 24 20 10 46 10 19 5 10 10 10 ICAAC Key words: antibacterial agent development approval 1946 60 238 10 Fig. 1 β 95 40 1976 1995 20 60 β β 40 chloramphenicol tetracycline

More information

Evaluation of the BIOGRAM Antimicrobial Susceptibility Test System

Evaluation of the BIOGRAM Antimicrobial Susceptibility Test System JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility

More information

Open Access. The Open Microbiology Journal, 2008, 2,

Open Access. The Open Microbiology Journal, 2008, 2, The Open Microbiology Journal, 2008, 2, 79-84 79 Open Access In vitro Antimicrobial Activity of Ampicillin-Ceftriaxone and Ampicillin- Ertapenem Combinations Against Clinical Isolates of Enterococcus faecalis

More information

RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN

RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN Hussein Azzam Bataineh 1 ABSTRACT Background: Vancomycin has been widely used in the treatment of infections caused by Methicillin-Resistant

More information

VLLM0421c Medical Microbiology I, practical sessions. Protocol to topic J05

VLLM0421c Medical Microbiology I, practical sessions. Protocol to topic J05 Topic J05: Determination of susceptibility of bacteria to antimicrobial drugs, assessments of resistance factors For study: textbooks, www, keywords e. g. Diffusion disc test ; E-test ; dilution micromethod

More information

Principles of Antimicrobial Therapy

Principles of Antimicrobial Therapy Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1

More information

Macrolide-Lincosamide-Streptogramin Resistance Patterns in

Macrolide-Lincosamide-Streptogramin Resistance Patterns in ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1981, p. 274-278 0066-4804/81/020274-05$02.00/0 Vol. 19, No. 2 Macrolide-Lincosamide-Streptogramin Resistance Patterns in Clostridium perfringens from Animals

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Antimicrobial susceptibility

Antimicrobial susceptibility Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects

Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 35 39 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa

More information

WHY IS THIS IMPORTANT?

WHY IS THIS IMPORTANT? CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change

More information

In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains

In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains Eur J Clin Microbiol Infect Dis (2010) 29:503 507 DOI 10.1007/s10096-010-0886-2 ARTICLE In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated

More information

Background and Plan of Analysis

Background and Plan of Analysis ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification

More information

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry

More information

Quality assurance of antimicrobial susceptibility testing

Quality assurance of antimicrobial susceptibility testing Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly

More information

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production

More information

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone

More information

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

Defining Resistance and Susceptibility: What S, I, and R Mean to You

Defining Resistance and Susceptibility: What S, I, and R Mean to You Defining Resistance and Susceptibility: What S, I, and R Mean to You Michael D. Apley, DVM, PhD, DACVCP Department of Clinical Sciences College of Veterinary Medicine Kansas State University Susceptible

More information

Resistance pattern of anaerobic bacteria isolated in a general hospital during a two-year period

Resistance pattern of anaerobic bacteria isolated in a general hospital during a two-year period Journal of Antimicrobial Chemotherapy (9), Supp. D, 9 6 Resistance pattern of anaerobic bacteria isolated in a general hospital during a two-year period J. F. Acar, F. W. Goldstein, M. D. Kitzis and M.

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

Performance Information. Vet use only

Performance Information. Vet use only Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.

More information

Volume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article

Volume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article Volume-7, Issue-2, April-June-2016 Coden IJABFP-CAS-USA Copyrights@2016 Received: 5 th Mar 2016 Revised: 11 th April 2016 Accepted: 13 th April 2016 Research article A STUDY ON ANTIBIOTIC SUSCEPTIBILITY

More information

EUCAST-and CLSI potency NEO-SENSITABS

EUCAST-and CLSI potency NEO-SENSITABS EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme

More information

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The

More information

BSAC standardized disc susceptibility testing method (version 8)

BSAC standardized disc susceptibility testing method (version 8) Journal of Antimicrobial Chemotherapy (2009) 64, 454 489 doi:10.1093/jac/dkp244 Advance Access publication 8 July 2009 BSAC standardized disc susceptibility testing method (version 8) J. M. Andrews* for

More information

Antimicrobials & Resistance

Antimicrobials & Resistance Antimicrobials & Resistance History 1908, Paul Ehrlich - Arsenic compound Arsphenamine 1929, Alexander Fleming - Discovery of Penicillin 1935, Gerhard Domag - Discovery of the red dye Prontosil (sulfonamide)

More information

Activity of Linezolid Tested Against Uncommonly Isolated Gram-positive ACCEPTED

Activity of Linezolid Tested Against Uncommonly Isolated Gram-positive ACCEPTED AAC Accepts, published online ahead of print on 8 January 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01496-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli. CRL Training course in AST Copenhagen, Denmark 23-27th Feb.

Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli. CRL Training course in AST Copenhagen, Denmark 23-27th Feb. Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli CRL Training course in AST Copenhagen, Denmark 23-27th Feb. 2009 Methodologies E-test by AB-biodisk A dilution test based on the

More information

Antimicrobial Susceptibility of Vancomycin-Resistant Leuconostoc, Pediococcus, and Lactobacillus Species

Antimicrobial Susceptibility of Vancomycin-Resistant Leuconostoc, Pediococcus, and Lactobacillus Species ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 99, p. 53-59 Vol. 3, No. 66-/9/53-7$./ Copyright C 99, American Society for Microbiology Antimicrobial Susceptibility of Vancomycin-Resistant,, and Species J.

More information

6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS

6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although

More information